Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;30(6):816-22.
doi: 10.1007/s11096-008-9232-5. Epub 2008 Jun 13.

Using the costs of drug therapy to screen patients for a community pharmacy-based medication review program

Affiliations

Using the costs of drug therapy to screen patients for a community pharmacy-based medication review program

Jean-Marc Krähenbühl et al. Pharm World Sci. 2008 Dec.

Abstract

Objectives: To measure the positive predictive value (PPV) of the cost of drug therapy (threshold = 2000 Swiss francs [CHF], US$1440, <euro>1360) as a screening criterion for identifying patients who may benefit from medication review (MR). To describe identified drug-related problems (DRPs) and expense problems (EPs), and to estimate potential savings if all recommendations were accepted.

Setting: Five voluntary Swiss community pharmacies.

Methods: Of 12,680 patients, 592 (4.7%) had drug therapy costs exceeding 2000 CHF over a six-month period from July 1 to December 31, 2002. This threshold limit was set to identify high-risk patients for DRPs and EPs. Three pharmacists consecutively conducted a medication review based on the pharmaceutical charts of 125 sampled patients who met the inclusion criterion.

Main outcome measure: The PPV of a threshold of 2000 CHF for identifying patients who might benefit from a MR: true positives were patients with at least one DRP, while false positives were patients with no DRP.

Results: The selection based on this criterion had a PPV of 86% for detecting patients with at least one DRP and 95% if EPs were also considered. There was a mean of 2.64 (SD = 2.20) DRPs per patient and a mean of 2.14 (SD = 1.39) EPs per patient. Of these patients, 90% were over 65 years old or were treated with at least five chronic medications, two common criteria for identifying patients at risk of DRPs. The main types of DRPs were drug-drug interactions, compliance problems and duplicate drugs. Mean daily drug cost per patient was CHF 14.87 (US$10.70, <euro>10.10). A potential savings of CHF 1.67 (US$1.20, <euro>1.14) per day (11%) was estimated if all recommendations to solve DRPs and EPs suggested herein were implemented.

Conclusion: Further studies should investigate whether the potential benefit of medication reviews in preventing DRPs and containing costs in this patient group can be confirmed in a real practice environment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Hosp Pharm. 1991 Feb;48(2):265-70 - PubMed
    1. BMJ. 2001 Dec 8;323(7325):1340-3 - PubMed
    1. Am J Med. 1996 Apr;100(4):428-37 - PubMed
    1. Fam Pract. 2006 Feb;23(1):46-52 - PubMed
    1. Pharm World Sci. 2004 Feb;26(1):18-25 - PubMed

Publication types

Substances

LinkOut - more resources